Cargando…

The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial

AIMS: N‐terminal pro‐b‐type natriuretic peptide (NT‐proBNP) values may be influenced by patient factors beyond the severity of illness, including atrial fibrillation (AF), renal dysfunction, or increased body mass index (BMI). We hypothesized that these factors may influence the achievement of NT‐pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ezekowitz, Justin A., Alemayehu, Wendimagegn, Rathwell, Sarah, Grant, Andrew D., Fiuzat, Mona, Whellan, David J., Ahmad, Tariq, Adams, Kirkwood, Piña, Ileana L., Cooper, Lawton S., Januzzi, James L., Leifer, Eric S., Mark, Daniel, O'Connor, Christopher M., Felker, G. Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787989/ https://www.ncbi.nlm.nih.gov/pubmed/34784657 http://dx.doi.org/10.1002/ehf2.13692

Ejemplares similares

Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction
por: Daubert, Melissa A., et al.
Publicado: (2021)

Clinical Implications of the New York Heart Association Classification
por: Caraballo, César, et al.
Publicado: (2019)

The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology
por: Kimmenade, Van, et al.
Publicado: (2007)

Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
por: Chouairi, Fouad, et al.
Publicado: (2021)

Natriuretic Peptide Testing in Primary Care
por: Rehman, Shafiq U, et al.
Publicado: (2008)

Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel
por: Psotka, Mitchell A., et al.
Publicado: (2020)

N‐terminal pro‐B‐type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction
por: Januzzi, James L., et al.
Publicado: (2021)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
por: Mohebi, Reza, et al.
Publicado: (2023)

Interaction of Body Mass Index on the Association Between N‐Terminal‐Pro‐b‐Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)
por: Bhatt, Ankeet S., et al.
Publicado: (2018)

Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles
por: Ahmad, Tariq, et al.
Publicado: (2016)

Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches
por: Stienen, Susan, et al.
Publicado: (2020)

Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
por: Mohebi, Reza, et al.
Publicado: (2023)

High vs. low oxygen therapy in patients with acute heart failure: HiLo‐HF pilot trial
por: Sepehrvand, Nariman, et al.
Publicado: (2019)

Utility of point-of-care testing of natriuretic peptides (brain natriuretic peptide and n-terminal pro-brain natriuretic peptide) in the emergency department
por: Nayer, Jamshed, et al.
Publicado: (2014)

Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19
por: Abraham, William T., et al.
Publicado: (2020)

Heart Failure Collaboratory Statement on Remote Monitoring and Social Distancing in the Landscape of COVID-19
por: Abraham, William T., et al.
Publicado: (2020)

NH(2)-Terminal Pro–Brain Natriuretic Peptide and Risk of Diabetes
por: Lazo, Mariana, et al.
Publicado: (2013)

Levels of N-terminal pro-brain natriuretic peptide in brain injury patients
por: Tsentsiper, L, et al.
Publicado: (2015)

Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
por: Ibrahim, Nasrien E., et al.
Publicado: (2020)

Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Ibrahim, Nasrien E., et al.
Publicado: (2020)

Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF
por: Felker, G. Michael, et al.
Publicado: (2021)

N-terminal Pro-Brain Natriuretic Peptide And Atrial Fibrillation
por: Thejus, Jayachandran, et al.
Publicado: (2009)

Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide
por: Riccardi, Mauro, et al.
Publicado: (2023)

Artificial Intelligence-Enabled Electrocardiography Detects B-Type Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide
por: Liu, Pang-Yen, et al.
Publicado: (2023)

A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort
por: Ezekowitz, Justin A., et al.
Publicado: (2017)

N-terminal pro brain natriuretic peptide in coronary artery disease
por: Tin, Sim Sai, et al.
Publicado: (2015)

N-Terminal Pro–B-Type Natriuretic Peptide and Incident CKD
por: Sasaki, Takaya, et al.
Publicado: (2021)

N‐Terminal Pro Brain, N‐Terminal Pro Atrial Natriuretic Peptides, and Dynamic Cerebral Autoregulation
por: Mahinrad, Simin, et al.
Publicado: (2020)

The Need for Fiber Addition in Symptomatic Heart Failure (FEAST-HF): A Randomized Controlled Pilot Trial
por: Colin-Ramirez, Eloisa, et al.
Publicado: (2023)

Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort
por: Welsh, Paul, et al.
Publicado: (2022)

Drotrecogin alfa (activated) reduces the plasma levels of N-terminal prohormone atrial natriuretic peptide and N-terminal prohormone brain natriuretic peptide as markers of cardiac depression in septic patients
por: Hoffmann, U, et al.
Publicado: (2004)

Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP)
por: Maries, Lorena, et al.
Publicado: (2013)

Effects of glutamine and valsartan on the brain natriuretic peptide and N-terminal pro-B-type natriuretic peptide of patients with chronic heart failure
por: Shao, Mingliang, et al.
Publicado: (2015)

Marked elevations in N-terminal brain natriuretic peptide levels in septic shock
por: Chua, Gerald, et al.
Publicado: (2004)

Reply to: N-terminal pro brain natriuretic peptide in coronary artery disease
por: Radwan, Hanan, et al.
Publicado: (2015)

N‐Terminal Pro‐C‐Natriuretic Peptide and Cytokine Kinetics in Dogs with Endotoxemia
por: Floras, A.N.K., et al.
Publicado: (2014)

N-terminal Pro-B-Type Natriuretic Peptide and Malnutrition in Patients on Hemodialysis
por: Ducros, Jacques, et al.
Publicado: (2020)

Resourcing Drug Development Commensurate With its Public Health Importance: The Road Ahead
por: Fiuzat, Mona, et al.
Publicado: (2016)

Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study
por: Januzzi, James L, et al.
Publicado: (2006)

Plasma atrial natriuretic peptide and N-terminal pro B-type natriuretic peptide concentrations in dogs with right-sided congestive heart failure
por: KANNO, Nobuyuki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_duk2p8v76qbn736dgphtvg9942